Our laboratory applies a variety of neurophysiologic techniques to explore normal and altered function in animal models and human clinical research. Experimental procedures include EEG, evoked potentials, ensemble and single unit recordings, current source density, and measures of whole nerve conduction velocity. Recently we have focused on developing sensitive biomarkers for the onset and progression of toxic neuropathies and seizure disorders. We have studied transgenic and mutant mice, models of diabetic neuropathy, compound-induced seizures, and demyelinating and iatrogenic deficits of central and peripheral nerve function. In parallel, we have participated in the “translation” of basic neuroscience principles to human clinical studies. We are currently involved in the design and conduct of multicenter Phase 1-4 clinical trials of experimental therapies intended to reduce or prevent diabetic and chemotherapy-induced neuropathies, to improve the treatment of chronic inflammatory demyelinating polyneuropathy, to explore treatment for ALS, and to monitor the modulation of pain. In this latter capacity, we have worked with the Centers for Disease Prevention and Control, the Environmental Protection Agency, the National Institute of Occupational Safety and Health and numerous pharmaceutical and biotechnology companies.

Zotova, E.G., Schaumburg, H.H., Raine, C.S., Cannella, B., Tar, M., Melman, A and Arezzo, J.C. Effects of hyperglycemia on rat cavernous nerve axons: a functional and ultrastructural study, Experimental Neurology 213:439­447, 2008.

Schaumburg, H.H., Arezzo, J.C., Lauria, G., Faber, C.G., Ingeman, S.J., Merkies. Morphometry of dermal nerve fibers in human skin. Neurology, 77(19):1770-1, 2011.

Arezzo, J.C., Litwak, M, and Zotova, E. Correlation and Dissociation of Electrophysiology andHistopathology in the Assessment of Toxic Neuropathy. Toxicologic Pathology 39:146­51, 2011.

Foster, W.R. Car, B.D., Shi, H, Levesque, P.C., Obemeier M.T., Gan, J., Arezzo, J.C. et al., Drug safety is a barrier to the discovery and development of new androgen receptoantagonist. Prostate 5:480­8, 2011.

Dyck, P.J., Albers. J.W., Andersen, H., Arezzo, J.C., Biessels, G.J., Bril, V., Feldman, E.L.,Litchy, W.J., O’Brien, P.C. and Russell, J.W. Diabetic polyneuropathies: Update on research definitions, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev, 2011.

Antoine, M.W., Hübner, C.A., Arezzo, J.C. and Hébert, J.M. A causative link between innerear defects and long-term striatal dysfunction, Science, 2013.

Arezzo, J.C., Seto, S. and Schaumburg, H.H. Sensory-Motor Assessment in Clinical Research Trials. Handbook of Clinical Neurology, Vol. 115, (3rd series) Peripheral Nerve Disorders, In: G. Said and C. Kraup, (Eds.), 2013.

Zotova, E.G. Arezzo, J.C. Non-invasive evaluation of nerve conduction in small diameterfibers in the rat. Physiology Journal, Article ID 254789, 2013.

Meta, M., Litwak M., and Arezzo, JA; Assessment of Seizure risk in pre-clinical Studies - Strenghs and limitations of EEG Journal of Pharmacology and Toxicological Methods, 2015

Long-Acting C-peptide and Neuropathy in Type 1 Diabetes – A 12-month Clinical Trial. Diabetes Care, 39:1-7, 2016

Authier, S, Arezzo, J, Delatte, M, Kallman, MJ, Margraff, C… Safety pharmacology investigation on the nervous system: An industry survey. Journal of Pharmacological and Toxicological Methods. 2016

Wieczorek, M, Tcherkezian, J, Bernier C., Prota, A, Chaaban, S, Rolland, Y, Godbout, C, Hancock M, Arezzo, J …. The synthetic diazonamide DZ-2384 has a distinct effect on microtubules curvature and dynamics without neurotoxicity, Science Translational Medicine, 2016.